The new ME/CFS Research Center at Mount Sinai in New York City is getting into gear fast. Following are some news bits regarding its activities, and comments from the center's coordinator, Dr. Derek Enlander* regarding emerging plans. Most important is the Sunday, Nov 20 public meeting for patients & doctors at Mt. Sinai (see below, and if you plan to attend register by Nov 17 as space is limited!).
On November 7, the XMRV Global Action facebook page posted this notice of a public meeting to share:
Event: ME/CFS Meeting at the New ME/CFS Center Mount Sinai, New York
Time: Sunday, November 20, 11 am to 2 pm
Location: Seminar Room, first floor Icahn Institute Mount Sinai Research Building 1425 Madison Avenue (at 98th Street), New York, NY
More Info: ME/CFS Meeting for Patients and Doctors - Topics will include "New Methods of Diagnosis and Treatment," including treatment summaries of GcMaf, Maf314, Maf878, Retuximab, CMX 001, Ampligen, Nexavir, Immunoprop etc. A late addition is a Methylation Cycle protocol. [Note: GcMAF, Ampligen, Hepapressin, and Immunoprop are treatments that Dr. Enlander is using.] Gene research will also be addressed.
Registration and Ticket Purchase: $30 in advance, $40 at door. To register so that your ticket(s) will be ready the day of the meeting, go to www.enlander.com/conference.html (If you wish to pay in advance online, click on "Add to Cart" for the Paypal link - you don't have to have a PayPal account). Let the organizers know you've registered so they can have your ticket for you at the door by emailing Dr Enlander at email@example.com
Speakers: Dr. Enlander will be speaking, as will be Dr. Eric Schadt, Dr Kenny DeMeirleir, Dr. David Bell, and Mt. Sinai immunologist Dr. Miriam Merad. Dr. Judy Mikovits and Dr. Jamie Deckoff-Jones will take part with the speakers in a closing panel discussion). [According to a Nov 7 post on the meeting by CFS Patient Advocate, Dr. Enlander has also announced that recent Mount Sinai recruits who will be involved in the ME/CFS Center include Dr. Schadt, who was appointed chair of the Genetics and Genomics Sciences Department at Mt. Sinai School of Medicine this summer, and retrovirologist Ila Singh, MD, PhD, from the University of Utah.]
On November 6, XMRV Global Action noted that:
Dr. Enlander has said on his facebook page that he and Dr. David Bell will attempt to replicate the Rituximab study, and that Dr. Bell is excited about coming to work on it with the team at the new ME/CFS Center in New York City.
On November 4, the European Society for ME (ESME) facebook page posted that:
“The Mount Sinai Medical Center has opened an ME/CFS clinical and research center in New York. This has been funded by a patient of Dr. Derek Enlander who donated a matching grant of $1 million. We encourage ESME members and patients to contribute to the fund. Contact Dr Enlander at firstname.lastname@example.org. Of course we encourage this as the ESME Team, to contribute funding to this new ME center in New York.”
And in October, Dr. Enlander told XMRV Global Action that he and his team at Mount Sinai are already initiating their first research cohort.
They are looking for ME/CFS patients who are twins, and Dr. Enlander asks, “If you are a twin or know of an ME/CFS patient who is a twin, I would like you to contact me on my email - email@example.com.")
* Dr. Enlander sees ME/CFS and fibromyalgia patients in his private practice in New York (www.enlander.com) as well as during visits to the UK, and is a faculty member and attending physician at Mount Sinai. He is also a member of the ESME scientific panel.